Literature DB >> 11333007

An "accidental" acute psychosis with ecstasy use.

G Vaiva1, V Boss, D Bailly, P Thomas, P Lestavel, M Goudemand.   

Abstract

Over the last 10 years, Europe has witnessed the development of the ecstasy phenomenon; this term is used to describe several products sharing more or less the same effects. The most widely used and hence the most well known is 3,4 MDMA, but MDA, MDEA, MBDB and even 2CB or nexus are available. The psychopathological consequences of MDMA use in man are relatively poorly understood. The case reported here involves an acute psychotic episode with residual symptoms after six months, with a sudden onset at least 12 hours after taking alcohol and ecstasy without realising it, in an individual with no previous psychopathology other than a moderate anxiety disorder. Twelve cases of acute psychotic episodes after taking ecstasy have been reported in the literature; two after taking the drug on two occasions and one after a single use. No authors have examined the previous mental state or possible previous psychopathology with any precision. The present subject had not displayed any previous psychotic behavior when tested with a proven standardized interview technique; this was confirmed by his peers and his family. He did, however, show signs of social phobia. Although the personality of an individual is a factor in taking a drug, and probably in the quality of the psychotropic effects experienced, a host of arguments favor the appearance of psychotic symptoms de novo, which were probably related to direct toxicity by MDMA and/or its metabolites on the serotoninergic neurons.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11333007     DOI: 10.1080/02791072.2001.10400473

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  3 in total

1.  Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.

Authors:  T Montgomery; C Buon; S Eibauer; P J Guiry; A K Keenan; G J McBean
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

Review 2.  3,4-methylenedioxymethamphetamine (MDMA): a review.

Authors:  G O'Leary; J Nargiso; R D Weiss
Journal:  Curr Psychiatry Rep       Date:  2001-12       Impact factor: 8.081

3.  Substance-induced anxiety disorder after one dose of 3,4-methylenedioxymethamphetamine: a case report.

Authors:  Kaeley Kaplan; Fiona Kurtz; Kelly Serafini
Journal:  J Med Case Rep       Date:  2018-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.